Bouf..ok...I do agree with this recent post of yours
RAF—we will never know for sure, but in my view there was a business deal that could have been made, and the problem was more likely AMRN’s overconfidence and not intransigence on the part of generics. This was not bet the company litigation for generics, who had much less to lose. AMRN should have retained control of its own destiny and made a deal.
But I get that this is my hindsight perspective, which is different from the one they had at the time. Pretty ironic given that they now have to convince the CTA that the district court should be reversed because of hindsight bias.
News 
Market Data 
Discover 
